From the Editor

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 5
Volume 17
Issue 5

To better engage our readership on the economic, policy, and practice issues affecting the oncology community, we have updated our editorial and changed our name, bringing more value-added content to the pages of Cancer Care Practice & Policy (CCP&P).

To better engage our readership on the economic, policy, and practice issues affecting the oncology community, we have updated our editorial and changed our name, bringing more value-added content to the pages of Cancer Care Practice & Policy (CCP&P). In the upcoming issues, our editors will develop regular columns on topics ranging from billing & coding problems to legal advice and practice management tips, all of which are designed to give quick-reading, issue-solving information for today’s busy oncologists.

Along with the regular feature departments, we will also report on the broader political actions and initiatives that influence the practice of oncology. To that end, we will continue to build our working relationship with ASCO, ASH, and ACCC to deliver consensus-driven views from leading experts on issues such as the impending work-force shortage of medical and gynecological oncologists, the challenges of implementing HIT, cancer care quality initiatives, and regulatory and advocacy issues.

As always, we encourage our readers to share their thoughts, advice, or opinions about anything that appears on these pages. [Please send comments to: Ronald.Piana@cmpmedica.com.]

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content